Clinical Trial Update: Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC [Phase 1]

View source ↗

Summary

Phase 1 trial investigating ceritinib in combination with docetaxel for ALK-negative, EGFR wild-type advanced non-small cell lung cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Zykadia (ceritinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non-small Cell Lung Cancer, Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING